| Summary: | Xuzhe Fu,1 Zhi Liu,2 Yu Wang1 1Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, People’s Republic of China; 2Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang, People’s Republic of ChinaCorrespondence: Yu Wang, Email wangy8@sj-hospital.orgAbstract: Sepsis is a life-threatening disease caused by a systemic infection that triggers a dysregulated immune response. Sepsis is an important cause of death in intensive care units (ICUs), poses a major threat to human health, and is a common cause of death in ICUs worldwide. The pathogenesis of sepsis is intricate and involves a complex interplay of pro- and anti-inflammatory mechanisms that can lead to excessive inflammation, immunosuppression, and potentially long-term immune disorders. Recent evidence highlights the importance of immunosuppression in sepsis. Immunosuppression is recognized as a predisposing factor for increased susceptibility to secondary infections and mortality in patients. Immunosuppression due to sepsis increases a patient’s chance of re-infection and increases organ load. In addition, antibiotics, fluid resuscitation, and organ support therapy have limited impact on the prognosis of septic patients. Therapeutic approaches by suppressing excessive inflammation have not achieved the desired results in clinical trials. Research into immunosuppression has brought new hope for the treatment of sepsis, and a number of therapeutic approaches have demonstrated the potential of immunostimulatory therapies. In this article, we will focus on the mechanisms of immunosuppression and markers of immune monitoring in sepsis and describe various targets for immunostimulatory therapy in sepsis.Keywords: sepsis, hyperinflammation, immunosuppression, immune cell
|
|---|